Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

634.O2.8 Biology of Myeloproliferative Disorders

Monday, December 8, 2008: 7:00 AM-9:00 AM
303-305-307 - South (Moscone Center)
Moderators:
Radek Skoda and Mingjiang Xu, Ph.D.
7:00 AM
Development of V617F JAK2 Associated Myeloproliferative Neoplasms Is a Non-Random Event That Is Strongly Dependent on JAK2 Haplotype

Nicholas C.P. Cross, PhD1, Amy V. Jones, BSc1*, Richard T. Silver, MD2, David Oscier, MD3*, Georgia Metzgeroth, MD4*, Y. Lynn Wang, MD, PhD5, Andrew Collins, PhD6*, Andreas Reiter, MD4*, Francis Grand, PhD1* and Andrew Chase, PhD1*

1Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom
2Weill Cornell Medical College, New York, NY
3Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
4III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
5Weill Medical College of Cornell, New York, NY
6Human Genetics Division, University of Southampton, Southampton, United Kingdom

7:15 AM
Frequent CBL Mutations Associated with 11q Acquired Uniparental Disomy in Myeloproliferative Neoplasms

Francis Grand, PhD1, Claire Hidalgo-Curtis, BSc1*, Thomas Ernst, MD1*, Katerina Zoi, PhD2*, Christine Zoi, MD2*, Carolann McGuire, PhD3*, Sebastian Kreil, MD4*, Georgia Metzgeroth, MD4*, David Oscier, MD5*, Andrew Hall, PhD6*, Christian Brandts, MD7*, Hubert Serve8*, Andreas Reiter, MD4*, Andrew Chase, PhD1* and Nicholas C.P. Cross, PhD1

1Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom
2Haematology Research Laboratory, Foundation of Biomedical Research of Academy of Athens, Athens, Greece
3Inflammation Infection and Repair Division, University of Southampton, Southampton, United Kingdom
4III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
5Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
6Newcastle University, Newcastle upon Tyne, United Kingdom
7Internal Medicine, University Hospital of Frankfurt, Frankfurt, Germany
8Dept. of Internal Medicine, University Hospital of Frankfurt, Frankfurt, Germany

7:30 AM
Molecular Mechanisms of JAK2V617F Oncogenic Activation: The JAK2-V617F Mutant Utilizes the SH2 Domain for Constitutive Kinase Activity in the Presence of Unstimulated Heterodimeric Cytokine Receptor.  

Sivahari P Gorantla, M.Sc.1*, Tobias Dechow, M.D2*, Rebekka Grundler, Ph.D3*, Christian Peschel, MD1 and Justus Duyster, prof.Dr1*

1Department of Hematology, Technical University of Munich, Munich, Germany
2Department of Hematology, Technical university of Munich, Munich, Germany
3dept.Hematology, Technical University of Munich, Munich, Germany

7:45 AM
Loss of Heterozygosity of Chromosome 1p34 and High Mutant Allele Burden in Patients with Post-Essential Thrombocythemia Myelofibrosis Carrying Somatic Mutations of MPL

Daniela Pietra1*, Elisa Rumi, MD1*, Angela Brisci2*, Francesco Passamonti, MD1*, Sabrina Boggi1*, Laura Cremonesi2*, Mario Lazzarino, MD1* and Mario Cazzola3

1Department of Hematology Oncology, University of Pavia & Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
2Genomic Unit for the Diagnosis of Human Pathologies, San Raffaele Scientific Institute, Milan, Italy
3Division of Hematology, University of Pavia Medical School, IRCCS Policlinico S. Matteo, Pavia, Italy

8:00 AM
Functional Determination of the Interaction Interface Between the Kinase and Pseudokinase Domains of JAK2 V617F

Alexandra Dusa1* and Stefan N. Constantinescu, MD, PhD2

1Ludwig Institute for Cancer Research, de Duve Institute, Université catholique de Louvain, Brussels, Belgium
2Brussels Branch of Cancer Genetics, Ludwig Inst. for Cancer Rsch., Brussels, Belgium

8:15 AM
Chromosomal Instability Causes Genetic and Clonal Heterogeneity in Myeloproliferative Neoplasms and Is Not Restricted to JAK2-V617F Positive Cells

Roland Jäger1*, Damla Olcaydu1*, Tiina Berg1*, Bettina Gisslinger2*, Heinz Gisslinger2 and Robert Kralovics1

1Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
2Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

8:30 AM
Dysregulated Expression of MicroRNA-16 Contributes to Abnormal Erythropoiesis in Patients with Polycythemia Vera

Paola Guglielmelli, MD1*, Lorenzo Tozzi, BiSci1*, Costanza Bogani, PhD1*, Niccolo' Bartalucci, BiSci1*, Simona Salati, PhD2*, Rossella Manfredini, MD2*, Alberto Bosi, MD1* and Alessandro M. Vannucchi, MD1

1Hematology, Università  degli Studi di Firenze, Firenze, Italy
2Biomedical Sciences, Università di Modena eReggio Emilia, Modena, Italy

8:45 AM
Transgenic Expression of Wild Type JAK2 Suppresses Myeloproliferative Disorder Phenotypes Induced by Mutant JAK2V617F in Mice

Shu Xing*, Wanming Zhao*, Wanting Tina Ho* and Zhizhuang Joe Zhao

Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

*signifies non-member of ASH